About Talactoferrin Alfa
Talactoferrin, a novel dendritic cell recruiter and activator (DCRA), is a unique recombinant form of human lactoferrin, an important immunomodulatory protein. Talactoferrin is an orally administered protein that mediates its activity through the gut and the GALT - the largest lymphoid organ in the body.
In 1988, scientists at Baylor College of Medicine, Houston, Texas, discovered a way to produce this protein in the laboratory, thus paving the way for testing its potential to help fight serious diseases that cause enormous suffering worldwide.
Lactoferrin, found in the highest concentration in milk, is expressed throughout the body in immune cells and on all body surfaces exposed to the external environment. Lactoferrin plays an important role in helping to establish the immune system, including the GALT, in infants. Talactoferrin is produced in Aspergillus niger, a filamentous fungus, and is structurally identical to native human lactoferrin in all material respects, differing only in its glycosylation.
Agennix is a private biotechnology company developing a first-in-class
molecule with activity in several types of cancer and in other indications
with unmet medical needs. This molecule, talactoferrin, is a targeted
dendritic cell recruiter and activator with a novel mechanism of action.
Agennix is preparing to initiate Phase 3 trials in two non-small cell lung
cancer indications (talactoferrin in combination with chemotherapy in
previously untreated patients and talactoferrin monotherapy in patients who
have failed two or more previous therapies), a Phase 2b trial in renal cell
|SOURCE Agennix, Inc.|
Copyright©2008 PR Newswire.
All rights reserved